Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice

Biochemical and Biophysical Research Communications

Volumn 437, Issue 2, 2013, Pages 287-291

  Xu, Guangwu ^a   Smith, Tameka ^a   Grey, Finn ^b   Hill, Ann B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer vaccine; Cytomegalovirus; Melanoma; Tyrosinase related protein 2

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DOPACHROME TAUTOMERASE; GLYCOPROTEIN L; MELANOMA VACCINE; MOUSE CYTOMEGALOVIRUS TYROSINASE RELATED PROTEIN 2 VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; VACCINATION;

CANCER VACCINE; CYTOMEGALOVIRUS; MELANOMA; TYROSINASE RELATED PROTEIN 2;

ANIMALS; CANCER VACCINES; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MUS;

EID: 84880716250     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.068     Document Type: Article

References (16)

1. Karrer U., Sierro S., Wagner M., Oxenius A., Hengel H., Koszinowski U.H., Phillips R.E., Klenerman P. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J. Immunol. 2003, 170:2022-2029.
2. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
3. Holtappels R., Pahl-Seibert M.F., Thomas D., Reddehase M.J. Enrichment of immediate-early 1 (m123/pp 89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J. Virol. 2000, 74:11495-11503.
4. Munks M.W., Cho K.S., Pinto A.K., Sierro S., Klenerman P., Hill A.B. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J. Immunol. 2006, 177:450-458.
5. Snyder C.M., Cho K.S., Bonnett E.L., van Dommelen S., Shellam G.R., Hill A.B. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 2008, 29:650-659.
6. Karrer U., Wagner M., Sierro S., Oxenius A., Hengel H., Dumrese T., Freigang S., Koszinowski U.H., Phillips R.E., Klenerman P. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J. Virol. 2004, 78:2255-2264.
7. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse A.W., Chiuchiolo M.J., Parks C.L., Axthelm M.K., Nelson J.A., Jarvis M.A., Piatak M., Lifson J.D., Picker L.J. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
8. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M., Lifson J.D., Nelson J.A., Jarvis M.A., Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
9. Lloyd M.L., Shellam G.R., Papadimitriou J.M., Lawson M.A. Immunocontraception is induced in BALB/c mice inoculated with murine cytomegalovirus expressing mouse zona pellucida 3. Biol. Reprod. 2003, 68:2024-2032.
10. Piechocki M.P., Pilon S.A., Wei W.Z. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 2002, 259:33-42.
11. Snyder C.M., Cho K.S., Bonnett E.L., Allan J.E., Hill A.B. Sustained CD8+ T cell memory inflation after infection with a single-cycle cytomegalovirus. PLoS Pathog 2011, 7:e1002295.
12. Klyushnenkova E.N., Kouiavskaia D.V., Parkins C.J., Caposio P., Botto S., Alexander R.B., Jarvis M.A. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J. Immunother. 2012, 35:390-399.
13. Guevara-Patino J.A., Engelhorn M.E., Turk M.J., Liu C., Duan F., Rizzuto G., Cohen A.D., Merghoub T., Wolchok J.D., Houghton A.N. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 2006, 116:1382-1390.
14. van Stipdonk M.J., Badia-Martinez D., Sluijter M., Offringa R., van Hall T., Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 2009, 69:7784-7792.
15. Orlandi F., Guevara-Patino J.A., Merghoub T., Wolchok J.D., Houghton A.N., Gregor P.D. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine 2011, 29:3646-3654.
16. Orlandi F., Venanzi F.M., Concetti A., Yamauchi H., Tiwari S., Norton L., Wolchok J.D., Houghton A.N., Gregor P.D. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin. Cancer Res. 2007, 13:6195-6203.